Healthcare

UAE investment drives AI-enabled biopharma and precision medicine

A new report says UAE investment in genomics, AI and advanced manufacturing is reshaping regional biopharma and precision medicine. The country is developing large genomic datasets and AI-enabled drug-discovery capabilities.

The available source reports that the UAE is investing in genomics, artificial intelligence and advanced manufacturing as part of a broader biopharmaceutical transformation. The initiative is connected to precision medicine, drug discovery and regional pharmaceutical production.

The Emirati Genome Program aims to collect one million genetic samples, while the UAE Reference Genome study is analyzing more than 50,000 samples. These datasets are intended to support disease prevention, precision treatment and healthcare research.

The report also describes Abu Dhabi’s HELM cluster, which is projected to attract substantial investment and create thousands of jobs. AI is presented as an enabling technology for identifying drug candidates, improving clinical-trial design and strengthening biopharmaceutical manufacturing.

The development matters because it positions the UAE as a regional hub for AI-enabled life-sciences research. The source also cites Insilico Medicine’s Abu Dhabi operations, where AI-discovered preclinical candidates in oncology and non-opioid pain were reportedly produced through discovery workflows completed in under 12 months.

Original source: Pharmaphorum

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI